Rheumatoid Arthritis Clinical Trials in Los Angeles

Showing 381-400 of 1,550 trials

ACTIVE_NOT_RECRUITINGPHASE1/PHASE2< 1 mile

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

NCT03162536

This study aims to evaluate the safety, tolerability, pharmacodynamic, and pharmacokinetic (PK) of nemtabrutinib (formerly ARQ 531) tablets in selected participants with relapsed or refractory hematologic malignancies. No formal hypothesis testing will be performed for this study.

Lymphoma, B-CellSmall Lymphocytic LymphomaChronic Lymphocytic Leukemia+6 more

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)190 participantsStarted Jun 2017

Scottsdale, Arizona, United States • Los Angeles, California, United States • Denver, Colorado, United States +7 more locations

COMPLETEDPHASE1< 1 mile

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

NCT04853017

This is a Phase 1 study to assess the safety and efficacy of ELI-002 immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[Amph-CpG-7909\] plus a mixture of lipid-conjugated peptide-based antigens \[Amph-Peptides\]) as adjuvant treatment of minimal residual disease (MRD) in subjects with KRAS/neuroblastoma ras viral oncogene homolog (NRAS) mutated PDAC or other solid tumors.

Minimal Residual DiseaseKRAS G12DKRAS G12R+9 more

Elicio Therapeutics25 participantsStarted Oct 2021

Duarte, California, United States • Los Angeles, California, United States • Aurora, Colorado, United States +7 more locations

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

Rheumatoid Arthritis Trials in Other Cities

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

FebriDx® Method Comparison Study Protocol

A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

1726-nm Laser for Acne Inversa (Hidradenitis Suppurativa)

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab

Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

The Use of Mentoring to Promote Well-being for Female SMART Members

Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

BlueWind RENOVA iStim™ System for the Treatment of OAB

Animal Assisted Intervention With Dogs for Children With ADHD

OCS DCD Heart + CAP Continued Follow-Up

Locking Plates for Distal Femur Fractures - a Multicenter Case Review

OCS-01 in Treating Inflammation and Pain in Post-cataract Patients

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma

Other Conditions in Los Angeles